Siren L.L.C. Trims Stock Holdings in Ascendis Pharma A/S $ASND

Key Points

• Siren L.L.C. has reduced its stake in Ascendis Pharma A/S by 3.3%, now holding 287,366 shares worth approximately $44.8 million.
• Ascendis Pharma reported earnings of ($0.93) per share for the last quarter, surpassing analyst expectations by $0.49.
• Multiple brokerages have recently upgraded their target prices for Ascendis Pharma, with Wells Fargo increasing their target from $289.00 to $295.00.

Siren L.L.C. lowered its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 287,366 shares of the biotechnology company's stock after selling 9,955 shares during the period. Ascendis Pharma A/S accounts for 2.6% of Siren L.L.C.'s investment portfolio, making the stock its 9th largest holding. Siren L.L.C. owned 0.47% of Ascendis Pharma A/S worth $44,789,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mariner LLC boosted its holdings in shares of Ascendis Pharma A/S by 31.0% in the fourth quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock valued at $297,000 after acquiring an additional 511 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Ascendis Pharma A/S by 195.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock valued at $138,000 after acquiring an additional 664 shares in the last quarter. Stifel Financial Corp boosted its holdings in shares of Ascendis Pharma A/S by 36.1% in the fourth quarter. Stifel Financial Corp now owns 17,097 shares of the biotechnology company's stock valued at $2,354,000 after acquiring an additional 4,534 shares in the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $230,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Ascendis Pharma A/S by 16.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 82,955 shares of the biotechnology company's stock valued at $11,420,000 after acquiring an additional 11,648 shares in the last quarter.

Ascendis Pharma A/S Price Performance

ASND traded up $1.00 during trading hours on Wednesday, reaching $200.16. 191,035 shares of the stock traded hands, compared to its average volume of 490,019. The firm's fifty day simple moving average is $180.96 and its two-hundred day simple moving average is $166.93. The company has a market cap of $12.25 billion, a price-to-earnings ratio of -38.79 and a beta of 0.39. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $203.59.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ASND shares. Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price objective for the company. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Wedbush lifted their target price on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $254.00 to $260.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 19th. Finally, Cowen reiterated a "buy" rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Fifteen research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $244.36.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.